# Merit Medical Systems Inc: financial statements, quarterly MMSI · Nasdaq · CIK 856982 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mmsi.md) · [Financials](/companies/mmsi/financials.md) · [Filings](/companies/mmsi/filings.md) · [Insiders](/companies/mmsi/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mmsi/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [325 d](/filings/0000856982-26-000008.md) | [324](/filings/0000856982-25-000027.md) | [338](/filings/0000856982-25-000046.md) | [340](/filings/0000856982-25-000056.md) | [355 d](/filings/0000856982-26-000008.md) | [355](/filings/0000856982-26-000025.md) | [382](/filings/0000856982-26-000044.md) | [384](/filings/0000856982-26-000052.md) | [394 d](/filings/0000856982-26-000008.md) | [382](/filings/0000856982-26-000025.md) | [419](/filings/0000856982-26-000044.md) | [416](/filings/0000856982-26-000052.md) | | Cost of revenue | $m | [174 d](/filings/0000856982-26-000008.md) | [172](/filings/0000856982-25-000027.md) | [177](/filings/0000856982-25-000046.md) | [182](/filings/0000856982-25-000056.md) | [182 d](/filings/0000856982-26-000008.md) | [183](/filings/0000856982-26-000025.md) | [198](/filings/0000856982-26-000044.md) | [198](/filings/0000856982-26-000052.md) | [199 d](/filings/0000856982-26-000008.md) | [197](/filings/0000856982-26-000025.md) | [204](/filings/0000856982-26-000044.md) | [216](/filings/0000856982-26-000052.md) | | Gross profit | $m | [151 d](/filings/0000856982-26-000008.md) | [152](/filings/0000856982-25-000027.md) | [161](/filings/0000856982-25-000046.md) | [158](/filings/0000856982-25-000056.md) | [173 d](/filings/0000856982-26-000008.md) | [172](/filings/0000856982-26-000025.md) | [184](/filings/0000856982-26-000044.md) | [186](/filings/0000856982-26-000052.md) | [195 d](/filings/0000856982-26-000008.md) | [185](/filings/0000856982-26-000025.md) | [215](/filings/0000856982-26-000044.md) | [201](/filings/0000856982-26-000052.md) | | Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Selling, general and administrative | $m | [95.8 d](/filings/0000856982-26-000008.md) | [94.4](/filings/0000856982-25-000027.md) | [94.6](/filings/0000856982-25-000046.md) | [99.6](/filings/0000856982-25-000056.md) | [111 d](/filings/0000856982-26-000008.md) | [107](/filings/0000856982-26-000025.md) | [113](/filings/0000856982-26-000044.md) | [120](/filings/0000856982-26-000052.md) | [115 d](/filings/0000856982-26-000008.md) | [118](/filings/0000856982-26-000025.md) | [129](/filings/0000856982-26-000044.md) | [120](/filings/0000856982-26-000052.md) | | Operating income | $m | [33.6 d](/filings/0000856982-26-000008.md) | [35.9](/filings/0000856982-25-000027.md) | [45.9](/filings/0000856982-25-000046.md) | [37.3](/filings/0000856982-25-000056.md) | [36.6 d](/filings/0000856982-26-000008.md) | [41.0](/filings/0000856982-26-000025.md) | [46.9](/filings/0000856982-26-000044.md) | [42.6](/filings/0000856982-26-000052.md) | [54.2 d](/filings/0000856982-26-000008.md) | [44.2](/filings/0000856982-26-000025.md) | [60.4](/filings/0000856982-26-000044.md) | [58.8](/filings/0000856982-26-000052.md) | | Interest expense | $m | [5.0 d](/filings/0000856982-24-000015.md) | [8.0](/filings/0000856982-24-000037.md) | [7.7](/filings/0000856982-25-000046.md) | [7.5](/filings/0000856982-25-000056.md) | [8.0 d](/filings/0000856982-26-000008.md) | [6.6](/filings/0000856982-26-000025.md) | [6.8](/filings/0000856982-26-000044.md) | [6.8](/filings/0000856982-26-000052.md) | [6.4 d](/filings/0000856982-26-000008.md) | [6.5](/filings/0000856982-26-000025.md) | [12.1](/filings/0000856982-26-000044.md) | [7.3](/filings/0000856982-26-000052.md) | | Income tax | $m | [3.8 d](/filings/0000856982-26-000008.md) | [6.1](/filings/0000856982-25-000027.md) | [10.1](/filings/0000856982-25-000046.md) | [8.2](/filings/0000856982-25-000056.md) | [5.2 d](/filings/0000856982-26-000008.md) | [7.8](/filings/0000856982-26-000025.md) | [10.8](/filings/0000856982-26-000044.md) | [10.8](/filings/0000856982-26-000052.md) | [13.1 d](/filings/0000856982-26-000008.md) | [12.6](/filings/0000856982-26-000025.md) | [12.5](/filings/0000856982-26-000044.md) | [13.5](/filings/0000856982-26-000052.md) | | Net income | $m | [27.6 d](/filings/0000856982-26-000008.md) | [28.2](/filings/0000856982-25-000056.md) | [35.7](/filings/0000856982-25-000056.md) | [28.4](/filings/0000856982-25-000056.md) | [27.9 d](/filings/0000856982-26-000008.md) | [30.1](/filings/0000856982-26-000052.md) | [32.6](/filings/0000856982-26-000052.md) | [27.8](/filings/0000856982-26-000052.md) | [38.0 d](/filings/0000856982-26-000008.md) | [41.0](/filings/0000856982-26-000052.md) | [38.8](/filings/0000856982-26-000052.md) | [42.3](/filings/0000856982-26-000052.md) | | Diluted EPS | $ per share | not reported | [0.48](/filings/0000856982-25-000027.md) | [0.61](/filings/0000856982-25-000046.md) | [0.48](/filings/0000856982-25-000056.md) | not reported | [0.49](/filings/0000856982-26-000025.md) | [0.54](/filings/0000856982-26-000044.md) | [0.46](/filings/0000856982-26-000052.md) | not reported | [0.68](/filings/0000856982-26-000025.md) | [0.65](/filings/0000856982-26-000044.md) | [0.70](/filings/0000856982-26-000052.md) | | Basic EPS | $ per share | not reported | [0.49](/filings/0000856982-25-000027.md) | [0.61](/filings/0000856982-25-000046.md) | [0.49](/filings/0000856982-25-000056.md) | not reported | [0.51](/filings/0000856982-26-000025.md) | [0.55](/filings/0000856982-26-000044.md) | [0.47](/filings/0000856982-26-000052.md) | not reported | [0.69](/filings/0000856982-26-000025.md) | [0.65](/filings/0000856982-26-000044.md) | [0.71](/filings/0000856982-26-000052.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: not reported - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [587](/filings/0000856982-26-000008.md) | [582](/filings/0000856982-25-000027.md) | [637](/filings/0000856982-25-000046.md) | [523](/filings/0000856982-25-000056.md) | [377](/filings/0000856982-26-000008.md) | [396](/filings/0000856982-26-000025.md) | [342](/filings/0000856982-26-000044.md) | [392](/filings/0000856982-26-000052.md) | [446](/filings/0000856982-26-000052.md) | [488](/filings/0000856982-26-000025.md) | [449](/filings/0000856982-26-000044.md) | [504](/filings/0000856982-26-000052.md) | | Current assets | $m | [1,108](/filings/0000856982-25-000011.md) | [1,105](/filings/0000856982-24-000037.md) | [1,163](/filings/0000856982-24-000078.md) | [1,078](/filings/0000856982-24-000096.md) | [924](/filings/0000856982-26-000008.md) | [959](/filings/0000856982-25-000027.md) | [923](/filings/0000856982-25-000046.md) | [986](/filings/0000856982-25-000056.md) | [1,040](/filings/0000856982-26-000052.md) | [1,102](/filings/0000856982-26-000025.md) | [1,112](/filings/0000856982-26-000044.md) | [1,199](/filings/0000856982-26-000052.md) | | Total assets | $m | [2,325](/filings/0000856982-25-000011.md) | [2,326](/filings/0000856982-24-000037.md) | [2,372](/filings/0000856982-24-000078.md) | [2,378](/filings/0000856982-24-000096.md) | [2,419](/filings/0000856982-26-000008.md) | [2,468](/filings/0000856982-25-000027.md) | [2,586](/filings/0000856982-25-000046.md) | [2,631](/filings/0000856982-25-000056.md) | [2,686](/filings/0000856982-26-000052.md) | [2,719](/filings/0000856982-26-000025.md) | [2,864](/filings/0000856982-26-000044.md) | [2,925](/filings/0000856982-26-000052.md) | | Current liabilities | $m | [204](/filings/0000856982-25-000011.md) | [183](/filings/0000856982-24-000037.md) | [186](/filings/0000856982-24-000078.md) | [201](/filings/0000856982-24-000096.md) | [216](/filings/0000856982-26-000008.md) | [197](/filings/0000856982-25-000027.md) | [226](/filings/0000856982-25-000046.md) | [230](/filings/0000856982-25-000056.md) | [240](/filings/0000856982-26-000052.md) | [217](/filings/0000856982-26-000025.md) | [265](/filings/0000856982-26-000044.md) | [265](/filings/0000856982-26-000052.md) | | Total liabilities | $m | [1,123](/filings/0000856982-25-000011.md) | [1,086](/filings/0000856982-24-000037.md) | [1,089](/filings/0000856982-24-000078.md) | [1,055](/filings/0000856982-24-000096.md) | [1,039](/filings/0000856982-26-000008.md) | [1,040](/filings/0000856982-25-000027.md) | [1,098](/filings/0000856982-25-000046.md) | [1,102](/filings/0000856982-25-000056.md) | [1,102](/filings/0000856982-26-000052.md) | [1,093](/filings/0000856982-26-000025.md) | [1,184](/filings/0000856982-26-000044.md) | [1,180](/filings/0000856982-26-000052.md) | | Long-term debt | $m | [823](/filings/0000856982-25-000011.md) | [800](/filings/0000856982-24-000037.md) | [801](/filings/0000856982-24-000078.md) | [751](/filings/0000856982-24-000096.md) | [730](/filings/0000856982-26-000008.md) | [731](/filings/0000856982-25-000027.md) | [732](/filings/0000856982-25-000046.md) | [733](/filings/0000856982-25-000056.md) | [734](/filings/0000856982-26-000052.md) | [735](/filings/0000856982-26-000025.md) | [736](/filings/0000856982-26-000044.md) | [737](/filings/0000856982-26-000052.md) | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [1,202](/filings/0000856982-26-000008.md) | [1,240](/filings/0000856982-25-000056.md) | [1,282](/filings/0000856982-25-000056.md) | [1,323](/filings/0000856982-25-000056.md) | [1,379](/filings/0000856982-26-000052.md) | [1,428](/filings/0000856982-26-000052.md) | [1,488](/filings/0000856982-26-000052.md) | [1,529](/filings/0000856982-26-000052.md) | [1,584](/filings/0000856982-26-000052.md) | [1,627](/filings/0000856982-26-000052.md) | [1,680](/filings/0000856982-26-000052.md) | [1,745](/filings/0000856982-26-000052.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: not reported - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [62.3 d](/filings/0000856982-26-000008.md) | [36.2](/filings/0000856982-25-000027.md) | [68.5 d](/filings/0000856982-25-000046.md) | [47.3 d](/filings/0000856982-25-000056.md) | [68.7 d](/filings/0000856982-26-000008.md) | [40.6](/filings/0000856982-26-000025.md) | [83.3 d](/filings/0000856982-26-000044.md) | [75.0 d](/filings/0000856982-26-000052.md) | [98.5 d](/filings/0000856982-26-000008.md) | [40.7](/filings/0000856982-26-000025.md) | [69.3 d](/filings/0000856982-26-000044.md) | [65.3 d](/filings/0000856982-26-000052.md) | | Capital expenditure | $m | [7.1 d](/filings/0000856982-26-000008.md) | [11.7](/filings/0000856982-25-000027.md) | [10.6 d](/filings/0000856982-25-000046.md) | [9.4 d](/filings/0000856982-25-000056.md) | [3.5 d](/filings/0000856982-26-000008.md) | [21.1](/filings/0000856982-26-000025.md) | [13.8 d](/filings/0000856982-26-000044.md) | [22.4 d](/filings/0000856982-26-000052.md) | [24.5 d](/filings/0000856982-26-000008.md) | [16.0](/filings/0000856982-26-000025.md) | [17.3 d](/filings/0000856982-26-000044.md) | [12.3 d](/filings/0000856982-26-000052.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [58.2](/filings/0000856982-24-000037.md) | [58.5](/filings/0000856982-24-000078.md) | [58.4](/filings/0000856982-24-000096.md) | [58.6](/filings/0000856982-25-000027.md) | [58.7](/filings/0000856982-25-000046.md) | [59.5](/filings/0000856982-25-000056.md) | [61.3](/filings/0000856982-26-000025.md) | [60.6](/filings/0000856982-26-000044.md) | [59.9](/filings/0000856982-26-000052.md) | [60.0](/filings/0000856982-26-000025.md) | [60.0](/filings/0000856982-26-000044.md) | [60.4](/filings/0000856982-26-000052.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 59,915,044 at 2026-10-27, from the cover of the [10-Q filed 2026-10-29](/filings/0000856982-26-000052.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 17:39 ET. No prices; not investment advice.